• STAT Plus: With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses

    4 days ago - By STAT

    Illumina, the dominant maker of machines to sequence DNA, is in talks to purchase Grail, a developer of a blood test to detect cancer that uses Illumina's technology.
    The discussions were first reported by Bloomberg News , and confirmed to STAT by a person with knowledge of the talks. The discussions could still fall apart at any time. Continue to STAT Plus to read the full story...
    Read more ...